Sodium-Glucose Cotransporter-2 Inhibitor Use and Lower Left Atrial Epicardial Adipose Tissue Volume Across Metabolic Phenotypes in Atrial Fibrillation

The authors aimed to determine whether the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) is associated with reduced left atrial epicardial adipose tissue volume (LA-EATV) in patients with atrial fibrillation (AF) undergoing ablation, and how this association varies across different metabolic phenotypes. Their findings indicate that SGLT2i use is linked to approximately 25% lower LA-EATV, with the association being stronger in patients with elevated triglyceride levels and weaker in those with higher body mass index. These results suggest a potential metabolic phenotype influence on the efficacy of SGLT2i in modifying LA-EATV, warranting further investigation.